Inhibition of EGFR using PD153035 significantly improves the pathological signs of non-alcoholic fatty liver disease (NAFLD), including glucose tolerance, pAKT signaling and expression of sterol responsive elementary binding protein (srebp) 1 and 2, key transcriptional regulators of de novo lipogenesis. Here, EGFR is linked to metabolic dysfunction-associated steatotic liver disease.